Concepedia

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun‐Sheng Huang, Jens Huober, Georgina Garnica Jaliffe, İrfan Çiçin,

The Lancet Oncology · 2022 · 566 citations · 21 references

DOIFull text

Open access

Concepts

References

21

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Journal of Clinical Oncology · 2018 · 2.5K citations · Full text

, , +15

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

M Baum, Aman U. Budzar, J Cuzick et al. · The Lancet · 2002 · 2K citations

, , +13

A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer

New England Journal of Medicine · 2005 · 1.6K citations · Full text

, , +9

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Journal of Clinical Oncology · 2020 · 986 citations · Full text

, , +17

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

M. Elizabeth H. Hammond, Daniel F. Hayes, Mitch Dowsett et al. · Archives of Pathology & Laboratory Medicine · 2010 · 896 citations

, , +14